Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dolphin Medical ServicesBOM:526504 36 Debt-to-EBITDA is 6.58 as of Mar. 2026. GuruFocus rates BOM:526504 with a GF Score™ of 36/100 and a GF Value™ of ₹2.40 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, Dolphin Medical Services ranks worse than 84.07% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Dolphin Medical Services's Debt-to-EBITDA or its related term are showing as below:
BOM:526504'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.37 Med: -4.66 Max: 812.39
Current: 5.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Dolphin Medical Services was 812.39. The lowest was -21.37. And the median was -4.66.
BOM:526504's Debt-to-EBITDA is ranked worse than 84.07% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.28
vs BOM:526504: 5.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dolphin Medical Services Debt-to-EBITDA Related Terms
Dolphin Medical Services Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526504 vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Dolphin Medical Services (BOM:526504) has a Debt-to-EBITDA of 6.58 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dolphin Medical Services. According to the industry distribution chart, Dolphin Medical Services ranks #95 out of 113 companies in the Medical Diagnostics & Research industry, placing it in the top 84.1%.
Is Dolphin Medical Services' Debt-to-EBITDA too high?
Dolphin Medical Services' current Debt-to-EBITDA is 6.58. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.28. Dolphin Medical Services' value of 6.58 is 188.6% above this industry median. Based on the distribution chart, Dolphin Medical Services ranks #95 out of 113 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dolphin Medical Services has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #95 out of 113 companies for Debt-to-EBITDA. This places Dolphin Medical Services in the lower half of its industry. The industry median Debt-to-EBITDA is 2.28. Dolphin Medical Services' value of 6.58 is 188.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.28, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dolphin Medical Services's current Debt-to-EBITDA of 6.58 is 188.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dolphin Medical Services. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dolphin Medical Services's current Debt-to-EBITDA is 6.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.40, compared to a current price of ₹7.20 — trading 200% above its estimated fair value. The current Debt-to-EBITDA is 6.58 and 188.6% above the Medical Diagnostics & Research industry median of 2.28. Dolphin Medical Services' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current Debt-to-EBITDA is 6.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹7.20 is trading 200% above its estimated GF Value™ of ₹2.40.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
Debt-to-EBITDA: 6.58
GF Value™: ₹2.40 vs. price of ₹7.20 (200% above fair value)
Industry Position: 188.6% above the Medical Diagnostics & Research median (#95 of 113)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
36GF Score
Get the complete analysis for BOM:526504
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
